Overview

Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants

Status:
Recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to determine functional target engagement of SAGE-904 using electrophysiological paradigms before and after ketamine administration.

Phase:

Phase 1

Details

Lead Sponsor:

Sage Therapeutics

Treatments:

Ketamine